{"generic":"Ulipristal Acetate","drugs":["Ella","Ulipristal Acetate"],"mono":{"0":{"id":"929677-s-0","title":"Generic Names","mono":"Ulipristal Acetate"},"1":{"id":"929677-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929677-s-1-4","title":"Adult Dosing","mono":"<ul><li>not indicated for routine contraception or for the termination of an existing pregnancy<\/li><li>not indicated in postmenopausal women<\/li><li>pregnancy is a contraindication for the use of ulipristal acetate and should be ruled out prior to administration of ulipristal acetate either by pregnancy testing or on the basis of a history and\/or physical examination.<\/li><li><b>Emergency contraception - Postcoital contraception:<\/b> 30 mg ORALLY as soon as possible within 120 hours (5 days) of unprotected intercourse or a known or suspected contraceptive failure; if vomiting occurs within 3 hours, consider repeating dose; repeated use within the same menstrual cycle is not recommended<\/li><\/ul>"},"1":{"id":"929677-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>not indicated in children before menarche<\/li><li>not indicated for routine contraception or for the termination of an existing pregnancy<\/li><li>pregnancy is a contraindication for the use of ulipristal acetate and should be ruled out prior to administration of ulipristal acetate either by pregnancy testing or on the basis of a history and\/or physical examination.<\/li><li><b>Emergency contraception - Postcoital contraception:<\/b> postpubertal adolescents, 30 mg ORALLY as soon as possible within 120 hours (5 days) of unprotected intercourse or a known or suspected contraceptive failure; if vomiting occurs within 3 hours, consider repeating dose; repeated use within the same menstrual cycle is not recommended<\/li><\/ul>"},"3":{"id":"929677-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Emergency contraception - Postcoital contraception<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Menorrhagia - Uterine leiomyoma, Preoperative<br\/>"}}},"3":{"id":"929677-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929677-s-3-9","title":"Contraindications","mono":"Pregnancy, known or suspected <br\/>"},{"id":"929677-s-3-10","title":"Precautions","mono":"<ul><li>Reproductive Effects<\/li><li>-- Ectopic pregnancy may occur; monitoring recommended<\/li><li>-- Not recommended for repeated use during same menstrual cycle<\/li><li>-- Return to fertility is rapid following use; initiate or continue barrier-method contraception for the remaining menstrual cycle<\/li><li>-- Exclude pregnancy if menses are delayed beyond 1 week; use may cause menses to occur earlier or later than expected<\/li><li>-- Intermenstrual bleeding has been reported<\/li><li>-- Use does not prevent HIV infection, AIDS, or other sexually transmitted diseases<\/li><li>-- Not for use in pediatric patients prior to menarche<\/li><li>-- Use in breastfeeding women not recommended<\/li><li>-- Use in postmenopausal women not recommended<\/li><li>Concomitant Use:<\/li><li>-- Avoid coadministration with CYP3A4 inducers (eg, topiramate, St. John's wort, rifampin, phenytoin)<\/li><li>-- Avoid concomitant use with hormonal contraceptives, contraceptive effect may be reduced; after taking ulipristal acetate, wait at least 5 days before using hormonal contraception and use barrier method until next menstrual period<\/li><\/ul>"},{"id":"929677-s-3-11","title":"Pregnancy Category","mono":"Ulipristal: X (FDA)<br\/>"},{"id":"929677-s-3-12","title":"Breast Feeding","mono":"Ulipristal: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929677-s-4","title":"Drug Interactions","sub":[{"id":"929677-s-4-13","title":"Contraindicated","mono":"<ul>Colchicine (theoretical)<\/ul>"},{"id":"929677-s-4-14","title":"Major","mono":"<ul><li>Afatinib (theoretical)<\/li><li>Aliskiren (theoretical)<\/li><li>Ambrisentan (theoretical)<\/li><li>Amobarbital (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Barbital (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Butabarbital (theoretical)<\/li><li>Butalbital (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Desogestrel (established)<\/li><li>Dienogest (established)<\/li><li>Digoxin (theoretical)<\/li><li>Drospirenone (established)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Ethynodiol Diacetate (established)<\/li><li>Etonogestrel (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Gestodene (established)<\/li><li>Hexobarbital (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Levonorgestrel (established)<\/li><li>Mephobarbital (theoretical)<\/li><li>Methohexital (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norethindrone (established)<\/li><li>Norgestimate (established)<\/li><li>Norgestrel (established)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pentobarbital (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Propranolol (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Rifaximin (theoretical)<\/li><li>Riociguat (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Silodosin (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sofosbuvir (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Talinolol (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Thiopental (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Vinblastine (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><\/ul>"}]},"5":{"id":"929677-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (8% to 15%), Nausea (12% to 13%)<\/li><li><b>Neurologic:<\/b>Headache (18% to 19%)<\/li><\/ul>"},"6":{"id":"929677-s-6","title":"Drug Name Info","sub":{"0":{"id":"929677-s-6-17","title":"US Trade Names","mono":"Ella<br\/>"},"2":{"id":"929677-s-6-19","title":"Class","mono":"Contraceptive<br\/>"},"3":{"id":"929677-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929677-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929677-s-7","title":"Mechanism Of Action","mono":"Ulipristal acetate is a synthetic progesterone agonist\/antagonist. It acts selectively on the human progesterone receptor and prevents progesterone from binding. When administered before ovulation, it postpones follicular rupture and therefore inhibits or delays ovulation. Additionally, ulipristal acetate alters the endometrium, which contributes to its efficacy by affecting implantation..<br\/>"},"8":{"id":"929677-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929677-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, oral: 0.9 hr<\/li><li>Effects of food: no impairment of efficacy or safety<\/li><\/ul>"},"1":{"id":"929677-s-8-24","title":"Distribution","mono":"Protein binding, HDL, alpha-1-acid glycoprotein, and albumin: greater than 94% <br\/>"},"2":{"id":"929677-s-8-25","title":"Metabolism","mono":"<ul><li>CYP3A4-mediated pathway<\/li><li>Monodemethyl-ulipristal acetate: active<\/li><\/ul>"},"4":{"id":"929677-s-8-27","title":"Elimination Half Life","mono":"<ul><li>32 +\/- 6.3 hr<\/li><li>Active metabolite: 27 +\/- 6.9 hr<\/li><\/ul>"}}},"9":{"id":"929677-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with or without food<\/li><li>may be taken at any time during the menstrual cycle<\/li><\/ul>"},"10":{"id":"929677-s-10","title":"Monitoring","mono":"<ul><li>pregnancy test; rule out pregnancy prior to initiation of treatment and following treatment if the onset of expected menses is beyond 1 week<\/li><li>history and\/or physical exam; to rule out pregnancy prior to initiation of treatment<\/li><\/ul>"},"11":{"id":"929677-s-11","title":"How Supplied","mono":"<b>Ella<\/b><br\/>Oral Tablet: 30 MG<br\/>"},"12":{"id":"929677-s-12","title":"Toxicology","sub":[{"id":"929677-s-12-31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"929677-s-12-32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"929677-s-12-33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},"13":{"id":"929677-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that drug does not prevent against HIV or other sexually transmitted diseases.<\/li><li>Advise patient to avoid ulipristal acetate if pregnancy is known or suspected.<\/li><li>This drug may cause acne, nausea, dizziness, headache, dysmenorrhea, or fatigue.<\/li><li>This drug may cause reduced contraceptive action of regular hormonal contraceptives and to use additional barrier contraceptive measures.<\/li><li>Advise patient to seek medical attention if their period is delayed by more than 1 week following the use of ulipristal acetate.<\/li><li>Advise patient to report severe abdominal pain 3 to 5 weeks following ulipristal acetate use; may indicate ectopic pregnancy.<\/li><li>Advise patient to take ulipristal acetate as soon as possible but no later than 120 hours (5 days) following unprotected intercourse or known or suspected contraceptive failure.<\/li><li>Advise patient not use ulipristal acetate as routine contraceptive or to repeat use during the same menstrual cycle.<\/li><li>When used for emergent, postcoital contraception, advise patient to contact healthcare professional if vomiting occurs within 3 hours of taking ulipristal acetate.<\/li><\/ul>"}}}